The BCKDHB Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated through targeted disruption of the BCKDHB gene in the HeLa cell line. This loss-of-function model facilitates investigation of branched-chain amino acid (BCAA) catabolism and BCKDH complex function. The polyclonal nature ensures representation of diverse editing outcomes, providing a robust cellular platform for downstream applications.
The HeLa host cell line is an immortalized human cervical adenocarcinoma line that is HPV18-positive and highly aneuploid. Widely employed in cancer research and general cell biology, HeLa cells offer robust growth, extensive characterization, and suitability for metabolic studies. Their epithelial origin and malignant background make them an ideal system for examining the interplay between BCAA metabolism and cervical cancer cell phenotypes.
BCKDHB encodes the E1?? subunit of the branched-chain alpha-keto acid dehydrogenase (BCKDH) complex, which catalyzes the oxidative decarboxylation of branched-chain ??-keto acids derived from leucine, isoleucine, and valine. The complex also includes the E1?? subunit (BCKDHA), the E2 transacylase (DBT), and the E3 dehydrogenase (DLD). BCKDH activity is tightly regulated by BCKDK-mediated phosphorylation (inactivation) and PPM1K-mediated dephosphorylation (reactivation). Downstream metabolites acetyl-CoA, succinyl-CoA, and acetoacetate enter the TCA cycle, linking BCAA catabolism to energy production. Gene disruption impairs complex assembly and function, leading to accumulation of BCAA-derived ??-keto acids and reduced TCA cycle anaplerosis.
In the HeLa cervical cancer context, BCKDHB knockout recapitulates key metabolic defects observed in maple syrup urine disease type II. The model allows dissection of how adenocarcinoma cells adapt to compromised BCAA oxidation, potentially revealing metabolic vulnerabilities or synthetic lethal interactions. Given the elevated BCAA demand in rapidly proliferating cancer cells, loss of BCKDHB may sensitize HeLa cells to nutrient restriction or shift their reliance on alternative carbon sources. This polyclonal knockout population thus serves as a valuable tool for studying BCKDH complex function in cancer metabolism, mitochondrial biology, and redox homeostasis.
Typical research applications include Western blotting and RT-qPCR to verify BCKDHB ablation, targeted metabolomics for BCAA and ??-keto acid quantification, and cell proliferation or viability assays under BCAA-depleted conditions. The cells are suitable for metabolic flux analysis using isotopically labeled BCAAs to trace carbon routing into the TCA cycle. They also enable screening of pharmacological reactivators of the BCKDH complex or modulators of its regulatory kinases and phosphatases. This product accelerates research into maple syrup urine disease, BCAA-dependent tumor pathways, and metabolic signaling. For additional information or custom services, please contact Ascent Research.
